SMSNA Meeting

"We found that the prevalence of both depression and anxiety were significantly higher in the men's health clinic," says Nestor F. Suria Cordero, MD.

"This is a phase 1 clinical trial, so we're primarily looking at safety and adverse events. We’ve had none in the 46 participants that we have so far," says David Alejandro Velasquez.

"It's really great because that means we can look at treating men sooner even if they're still presenting, and in what we would traditionally or classically call the acute phase, we're able to offer an FDA approved therapy at an earlier timeline," says Jesse N. Mills, MD.

“Completing those 4 injection cycles is likely to yield the best clinical outcomes for most of our patients,” says Matthew J. Ziegelmann, MD.

"We didn't see any clinically significant changes on the prostate gland, which is very important for the urologists who see people who have prostate cancer or prostate enlargement," says Ronald Swerdloff, MD.

In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Kevin J. Campbell, MD, MS, and a team of investigators examined the correlations between finasteride and drugs used to treat hypogonadism and sexual dysfunction in order to understand how best to prescribe this medication in terms of lowering adverse drug reactions.

“Both [IMPRESS trials] would suggest that if patients are motivated to see if they can continue to improve their curvature and avoid things like surgery—which for many patients…is a goal—continuing with the collagenase makes good sense,” says Matthew J. Ziegelmann, MD.

“Always look at the patient as…a whole and not only [their] testosterone levels,” says Karim Sultan Haider, MD.

In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Jay Newmark, MD, MBA, and co-authors report promising findings on the first experiences of patients using JATENZO in the real world.

“What's most important [is] that…one dose does not just fit all,” says Martin M. Miner, MD.

“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

In a recent study Martin M. Miner, MD, and co-authors investigated the effect of BMI on the pharmacokinetic profile or dosing of testosterone therapies in men with TD.

“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.

“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.

“Most importantly, the improvement that they were able to get during the first couple of years is sustained, whereas what we expect in untreated men [is that] their erectile function…keeps on deteriorating,” says Karim Sultan Haider, MD.

“I think the most exciting thing in the Sexual Medicine sphere is the stride for equity, diversity, and inclusion,” says Jesse N. Mills, MD.

“This study suggests that the treatment of a patient's underlying hypogonadism or sexual dysfunction may be protective in the use of finasteride for alopecia or BPH,” says Kevin J. Campbell, MD, MS.

“Additional Peyronie’s disease therapies are needed as current treatment modalities have limited efficacy and considerable side effects," the authors wrote.

According to the investigators, their findings were consistent with initial real-world experience with oral testosterone undecanoate indicating that dose titration is not required in most patients.

“The difference between this compound and other compounds that were orally administered, is that this seems to go through the lymphatic system rather than going directly to the liver,” says Ronald Swerdloff, MD.

By the end of a 12-week period, total testosterone C-trough, C-avg (0 to 168 hours), and C-max were inversely related to BMI.

“What we wanted to do was to substantiate any difference between BPH and alopecia with finasteride and also people who are concomitantly taking testosterone for hypogonadism,” says Kevin J. Campbell, MD, MS.

Over the observation period, 15 patients (8.2%) in the treatment group died compared with 61 patients (34.3%) in the control group.

Although there was no significant change in the erect or the stretched penile length in patients who responded to the injections, results showed that there was a significant decrease in the erect circumference among the majority of patients.

“There's 3 different levels of dosing…so this does provide you with a mechanism for titration if you're going to be using that in your patients,” says Jesse N. Mills, MD.

There were no clinically significant changes in liver function tests throughout the 2 trials.

“The initial levels were inversely related to body mass index, so…men who are the largest…or had the largest BMI have the lowest testosterone levels,” says Martin M. Miner, MD.

“In our cohort, [diabetes mellitus] was a significant predictor of lower [erectile function recovery] at 2 years post-RP,” the authors wrote.

“Results would suggest benefits with performing a full series of 4 CCH injections, even among men who are initial non-responders,” the authors concluded.

International Index of Erectile Function-Erectile Function (IIEF-EF) score increased in patients receiving nutraceuticals.